SCHEMBL402480

SCHEMBL402480

O=C(O)C1C[C@@H](OCc2ccccc2)C(O)CO1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 3/20 0.46
PDE4D Q08499 1/20 0.43
PSEN1 P49768 2/20 0.39
PSEN2 P49810 2/20 0.39
APH1B Q8WW43 2/20 0.39
NCSTN Q92542 2/20 0.39
APH1A Q96BI3 2/20 0.39
PSENEN Q9NZ42 2/20 0.39
KLK7 P49862 1/20 0.39
KLK5 Q9Y337 1/20 0.39
ALDH1A1 P00352 3/20 0.38
CTSV O60911 1/20 0.38
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
CTSC P53634 1/20 0.38
CTSF Q9UBX1 1/20 0.38
SLC6A2 P23975 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14478960 1.00 BCHE (0.46) BCHEPDE4DPSEN1PSEN2APH1B
SCHEMBL14478947 0.89 BCHE (0.51) BCHEPDE4DPSEN1PSEN2APH1B
SCHEMBL404367 0.88 BCHE (0.44) BCHEPDE4DKLK7KLK5ALDH1A1
SCHEMBL16232447 0.87 BCHE (0.46) BCHEPDE4DPSEN1PSEN2APH1B
SCHEMBL31629437 0.81 CTSL (0.44) BCHEALDH1A1CTSLCTSBCTSK
SCHEMBL19403045 0.81 CTSL (0.44) BCHEALDH1A1CTSLCTSBCTSK
SCHEMBL404025 0.81 BCHE (0.45) BCHEPDE4DPSEN1PSEN2APH1B
SCHEMBL14478945 0.81 BCHE (0.45) BCHEPDE4DPSEN1PSEN2APH1B
SCHEMBL402691 0.79 PDE4D (0.49) BCHEPDE4DPSEN1PSEN2APH1B
SCHEMBL25319621 0.78 PDE4D (0.51) BCHEPDE4DPSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF SANOFI-AVENTIS (FR) 2012-03-15 US disclosed
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof SANOFI-AVENTIS (FR) 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF HPSE, HAAO, HEXD BCHE 1419/4885PDE4D 3160/4885PSEN1 4227/4885
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof HPSE, HAAO, HEXD BCHE 1409/4885PDE4D 3189/4885PSEN1 4200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.